NCI-2022-10844

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors

This Phase 1/1b study is investigating a drug called RMC-6291 as a monotherapy in subjects with advanced solid tumors that have a specific genetic mutation called KRAS G12C. The study is multicenter and open-label, meaning that researchers and participants are aware of the treatment being administered. The main objectives of the study are to evaluate the safety, determine the appropriate dosage levels (dose escalation), and assess the effectiveness of RMC-6291 in treating advanced solid tumors with the KRAS G12C mutation

KRAS: a specific type of alteration in the KRAS gene, which is part of the RAS gene family. These mutations can lead to uncontrolled cell growth and are commonly found in various cancers, impacting treatment outcomes and guiding therapeutic strategies.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05462717

Clinical Trial Site: Columbia

To see all available clinical trials click here.